Ellsworth Advisors, LLC Nuvalent, Inc. Transaction History

Ellsworth Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 18, 2024	SELL	$42.42 - $80.28 $21,846 - $41,344	-515 Reduced 4.41%	11,176 $822,000
Q3 2023 Oct 20, 2023	SELL	$39.12 - $49.85 $1,603 - $2,043	-41 Reduced 0.35%	11,691 $537,000
Q2 2023 Jul 24, 2023	BUY	$23.58 - $44.68 $8,960 - $16,978	380 Added 3.35%	11,732 $494,000
Q1 2023 Apr 12, 2023	BUY	$25.42 - $33.52 $12,227 - $16,123	481 Added 4.42%	11,352 $296,000
Q4 2022 Jan 19, 2023	BUY	$18.46 - $36.37 $200,678 - $395,378	10,871 New	10,871 $0

210

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $4.08B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Ellsworth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Ellsworth Advisors, LLC with notifications on news.